Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 447

1.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee.

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

2.

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH.

J Bone Miner Res. 2011 May;26(5):993-1001. doi: 10.1002/jbmr.288.

3.

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.

Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L.

Osteoporos Int. 2011 Mar;22(3):993-1001. doi: 10.1007/s00198-010-1512-y. Epub 2010 Dec 17.

PMID:
21165600
4.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Nieves JW, Cosman F.

Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Review.

PMID:
20425089
5.

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Abrahamsen B, Eiken P, Eastell R.

J Clin Endocrinol Metab. 2010 Dec;95(12):5258-65. doi: 10.1210/jc.2010-1571. Epub 2010 Sep 15.

6.

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.

Capeci CM, Tejwani NC.

J Bone Joint Surg Am. 2009 Nov;91(11):2556-61. doi: 10.2106/JBJS.H.01774.

PMID:
19884427
7.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

8.

Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.

Chang ST, Tenforde AS, Grimsrud CD, O'Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC.

Bone. 2012 Sep;51(3):524-7. doi: 10.1016/j.bone.2012.05.010. Epub 2012 May 23.

PMID:
22634175
9.

Evolving data about subtrochanteric fractures and bisphosphonates.

Shane E.

N Engl J Med. 2010 May 13;362(19):1825-7. doi: 10.1056/NEJMe1003064. Epub 2010 Mar 24. No abstract available.

PMID:
20335574
10.

Bisphosphonate-related subtrochanteric femoral fractures.

Gunawardena I, Baxter M, Rasekh Y.

Am J Geriatr Pharmacother. 2011 Jun;9(3):194-8. doi: 10.1016/j.amjopharm.2011.02.009. Epub 2011 Apr 5.

PMID:
21470918
11.

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C.

Osteoporos Int. 2011 Feb;22(2):373-90. doi: 10.1007/s00198-010-1453-5. Epub 2010 Nov 18. Review.

12.

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

John Camm A.

Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Review.

PMID:
20399982
13.

Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.

Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ.

J Bone Joint Surg Am. 2011 Jul 6;93(13):1235-42. doi: 10.2106/JBJS.J.01199.

PMID:
21776577
14.

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Abrahamsen B, Eiken P, Eastell R.

J Bone Miner Res. 2009 Jun;24(6):1095-102. doi: 10.1359/jbmr.081247.

15.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012
16.

Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.

Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG.

J Bone Joint Surg Br. 2012 Mar;94(3):385-90. doi: 10.1302/0301-620X.94B3.27999.

PMID:
22371548
17.

What do we know about atypical femoral fractures? Insights and enigmas.

Audran M, Cortet B, Thomas T; Bone division of the French Society for Rheumatology.

Joint Bone Spine. 2011 Dec;78(6):568-71. doi: 10.1016/j.jbspin.2011.03.015. Epub 2011 May 17. Review.

PMID:
21592839
18.

Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.

Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, Tsai YW.

Clin Ther. 2011 Nov;33(11):1659-67. doi: 10.1016/j.clinthera.2011.09.006. Epub 2011 Oct 22.

PMID:
22018450
19.

Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.

Patel VC, Lazzarini AM.

Orthopedics. 2010 Oct 11;33(10):775. doi: 10.3928/01477447-20100826-31.

PMID:
20954650
20.

Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.

Bamrungsong T, Pongchaiyakul C.

J Med Assoc Thai. 2010 May;93(5):620-4.

PMID:
20524451
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk